Literature DB >> 11146381

Epidemiology of osteoporotic fractures.

E Dennison1, C Cooper.   

Abstract

Osteoporosis constitutes a major public health problem through its association with age-related fractures. These fractures typically occur at the hip, spine and distal forearm. It has been estimated that the lifetime risk of a hip fracture in white women is 17.5%, with a comparable risk in men of 6%. Hip fractures lead to an overall reduction in survival of about 15% (relative or observed/expected survival at 5 years of 0.83), and the majority of excess deaths occur within the first 6 months following the fracture. Such fractures are also associated with considerable morbidity. Although all vertebral deformities do not come to clinical attention, the lifetime risk of clinically diagnosed vertebral fractures is about 15% in white women. Vertebral fractures tend to be associated with back pain and kyphosis, and also with an impairment of survival, though this is likely to be due to clustering of comorbidity. About one-quarter of clinically diagnosed vertebral deformities result in hospitalization. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2000        PMID: 11146381     DOI: 10.1159/000063449

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  41 in total

1.  Percutaneous vertebroplasty versus balloon kyphoplasty for treatment of osteoporotic vertebral compression fracture: a meta-analysis of randomised and non-randomised controlled trials.

Authors:  Shiliang Han; Shuanglin Wan; Lei Ning; Yongjun Tong; Jianfeng Zhang; Shunwu Fan
Journal:  Int Orthop       Date:  2011-06-03       Impact factor: 3.075

2.  Efficacy and safety of bazedoxifene in postmenopausal Asian women.

Authors:  L Xu; K-S Tsai; G S Kim; Y Wu; P Vincendon; A A Chines; G D Constantine
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

3.  Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.

Authors:  T J de Villiers; A A Chines; S Palacios; P Lips; A Z Sawicki; A B Levine; C Codreanu; N Kelepouris; J P Brown
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

4.  High heritability of bone size at the hip and spine in Chinese.

Authors:  Wei-Xia Jian; Ji-Rong Long; Hong-Wen Deng
Journal:  J Hum Genet       Date:  2004-01-15       Impact factor: 3.172

Review 5.  Fixation principles in metaphyseal bone--a patent based review.

Authors:  R Curtis; J Goldhahn; R Schwyn; P Regazzoni; N Suhm
Journal:  Osteoporos Int       Date:  2004-11-03       Impact factor: 4.507

6.  Lordoplasty: report on early results with a new technique for the treatment of vertebral compression fractures to restore the lordosis.

Authors:  Rene Orler; Lars H Frauchiger; Uta Lange; Paul F Heini
Journal:  Eur Spine J       Date:  2006-05-25       Impact factor: 3.134

7.  Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.

Authors:  J Feber; I Gaboury; A Ni; N Alos; S Arora; L Bell; T Blydt-Hansen; C Clarson; G Filler; J Hay; D Hebert; B Lentle; M Matzinger; J Midgley; D Moher; M Pinsk; F Rauch; C Rodd; N Shenouda; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2011-04-15       Impact factor: 4.507

8.  Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice.

Authors:  Amel Dudakovic; Emily T Camilleri; Scott M Riester; Christopher R Paradise; Martina Gluscevic; Thomas M O'Toole; Roman Thaler; Jared M Evans; Huihuang Yan; Malayannan Subramaniam; John R Hawse; Gary S Stein; Martin A Montecino; Meghan E McGee-Lawrence; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2016-10-10       Impact factor: 5.157

Review 9.  Denosumab for joints and bones.

Authors:  E Michael Lewiecki
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

10.  Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.